CN114431412A - 一种安全高效溶解血栓和脂质斑块的营养组合物 - Google Patents
一种安全高效溶解血栓和脂质斑块的营养组合物 Download PDFInfo
- Publication number
- CN114431412A CN114431412A CN202111620451.1A CN202111620451A CN114431412A CN 114431412 A CN114431412 A CN 114431412A CN 202111620451 A CN202111620451 A CN 202111620451A CN 114431412 A CN114431412 A CN 114431412A
- Authority
- CN
- China
- Prior art keywords
- parts
- nutritional composition
- portions
- powder
- plaque
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 35
- 235000016709 nutrition Nutrition 0.000 title claims abstract description 32
- 208000007536 Thrombosis Diseases 0.000 title claims abstract description 21
- 150000002632 lipids Chemical class 0.000 title claims abstract description 11
- 239000000843 powder Substances 0.000 claims abstract description 43
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 30
- 235000013557 nattō Nutrition 0.000 claims abstract description 23
- 210000002216 heart Anatomy 0.000 claims abstract description 22
- 241001494479 Pecora Species 0.000 claims abstract description 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 18
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract description 15
- 229940026314 red yeast rice Drugs 0.000 claims abstract description 15
- 229960003080 taurine Drugs 0.000 claims abstract description 15
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 14
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 14
- PYMYPHUHKUWMLA-LMVFSUKVSA-N aldehydo-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 14
- 108090000623 proteins and genes Proteins 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- 241000361919 Metaphire sieboldi Species 0.000 claims description 12
- 235000007688 Lycopersicon esculentum Nutrition 0.000 claims description 9
- 240000003768 Solanum lycopersicum Species 0.000 claims description 9
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 7
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 7
- 239000012141 concentrate Substances 0.000 claims description 7
- 235000013361 beverage Nutrition 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 7
- 239000008280 blood Substances 0.000 abstract description 7
- 206010020772 Hypertension Diseases 0.000 abstract description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 3
- 201000001320 Atherosclerosis Diseases 0.000 abstract description 2
- 206010057469 Vascular stenosis Diseases 0.000 abstract description 2
- 230000036770 blood supply Effects 0.000 abstract description 2
- 210000004556 brain Anatomy 0.000 abstract description 2
- 230000002526 effect on cardiovascular system Effects 0.000 abstract description 2
- 230000007505 plaque formation Effects 0.000 abstract description 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 230000017531 blood circulation Effects 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 210000004204 blood vessel Anatomy 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 238000002604 ultrasonography Methods 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 210000001168 carotid artery common Anatomy 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000002537 thrombolytic effect Effects 0.000 description 5
- 230000002146 bilateral effect Effects 0.000 description 4
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 210000003270 subclavian artery Anatomy 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 206010047163 Vasospasm Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000001715 carotid artery Anatomy 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 2
- 108010088842 Fibrinolysin Proteins 0.000 description 2
- 229940123457 Free radical scavenger Drugs 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 description 2
- 229940110767 coenzyme Q10 Drugs 0.000 description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 244000113306 Monascus purpureus Species 0.000 description 1
- 235000002322 Monascus purpureus Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 235000007189 Oryza longistaminata Nutrition 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 240000008467 Oryza sativa Japonica Group Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 206010046996 Varicose vein Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000269 carotid artery external Anatomy 0.000 description 1
- 210000004004 carotid artery internal Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000013367 dietary fats Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229940001501 fibrinolysin Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 108010070324 lumbrokinase Proteins 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000003818 metabolic dysfunction Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229940057059 monascus purpureus Drugs 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 229940086319 nattokinase Drugs 0.000 description 1
- 108010073682 nattokinase Proteins 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000019614 sour taste Nutrition 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 210000004026 tunica intima Anatomy 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000012856 weighed raw material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L11/00—Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
- A23L11/50—Fermented pulses or legumes; Fermentation of pulses or legumes based on the addition of microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/09—Mashed or comminuted products, e.g. pulp, purée, sauce, or products made therefrom, e.g. snacks
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
- A23L7/104—Fermentation of farinaceous cereal or cereal material; Addition of enzymes or microorganisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Agronomy & Crop Science (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开了一种安全高效溶解血栓和脂质斑块的营养组合物,所述营养组合物由重量份如下的各组分组成:纳豆冻干粉10‑20份、红曲6‑15份、羊心肽10‑15份、金银花6‑10份、葛根粉6‑10份和牛磺酸1‑2份。本发明中的营养组合物可转化成心脑血管类基础疾病预防和治疗的产品,适用高脂血症、血液黏稠、动脉粥样硬化、斑块形成及斑块导致血管狭窄、高血压等所导致的心脏、大脑及全身组织发生的供血不足等。
Description
技术领域
本发明涉及保健品技术领域,具体而言,涉及一种安全高效溶解血栓和脂质斑块的营养组合物。
背景技术
社会的高速发展及人们不健康的生活方式,造成精神压力过大和代谢功能紊乱,导致人体内血脂偏高、血管痉挛和血管内皮受损,从而导致血液里的胆固醇酯进入到血管内膜下逐渐累积形成斑块,斑块越累积越大,血管管腔越来越狭窄,最终导致血管栓塞。目前市场上针对动脉血管壁里的脂质斑块的治疗方法,为用药物或健字号的产品抗凝或扩张血管缓解症状,严重的进行手术给予放支架或开胸搭桥手术。现有治疗动脉血管中斑块的方法中,药物或健字号产品治疗既也不能缩小斑块也不能阻止斑块生长;而支持和开胸搭桥手术虽然可以快速地缩小斑块和恢复血流的通畅,但是对病人损耗大。
且即使使用药物溶栓,溶栓时会加大继发出血的风险,甚至为禁忌,且溶栓治疗的时间窗要求严格,造成溶栓对大部分病人的治疗出现技术上障碍,影响预防后及生存质量。
发明内容
本发明正是基于上述技术问题至少之一,本发明提供一种安全高效溶解血栓和脂质斑块的营养组合物,本发明中的营养组合物可转化成心脑血管类基础疾病预防和治疗的产品,适用高脂血症、血液黏稠、动脉粥样硬化、斑块形成及斑块导致血管狭窄、高血压等所导致的心脏、大脑及全身组织发生的供血不足等。
有鉴于此,根据本发明的第一个目的提出了一种安全高效溶解血栓和脂质斑块的营养组合物,所述营养组合物由重量份如下的各组分组成:纳豆冻干粉10-20份、红曲6-15份、羊心肽10-15份、金银花6-10份、葛根粉6-10份和牛磺酸1-2份。
其中本发明实施例中纳豆冻干粉是固体发酵的纳豆,经过零下40摄氏度冻结后,经真空抽湿升华干燥、粉碎,成为纳豆冻干粉。纳豆冻干粉最大限度地保留了纳豆中的生理活性物质——纳豆激酶,具有溶化血栓、有效预防和改善冠心病、高血压、动脉硬化、中风、静脉曲张的功效,还可提高免疫系统。
地龙蛋白提取自地龙,含有胶原酶、纤溶酶、蚓激酶、纤溶激活蛋白(FA蛋白)、核酸、微量元素等多种成分,不仅具有解热、镇静、抗惊厥作用,而且还有明显的抑制血栓形成的作用。
红曲,为曲霉科真菌红曲霉的菌丝体寄生在粳米上而成的红曲米,其性温,味甘,归肝经、脾经、大肠经。红曲发酵后可分离到辅酶Q10,辅酶Q10是细胞代谢及细胞呼吸的激活剂,促进氧化磷酸化反应,其是天然氧化剂免疫有非特异的增强作用,能提高吞噬细胞的吞噬率,增加抗体的产生,改善T细胞功能,因此红曲不仅具有活血化瘀,还具有健脾消食的作用。
羊心肽为羊心提取物蛋白质,包含脂肪,硫胺素,核黄素,维生素A,钙元素,铁元素,磷元素等成分,可以提供丰富的营养物质给人体,增强体质,提高机体免疫力和抗病能力,不仅能给人体补充钾元素降低血压,缓解心血管疾病;而且羊心肽中富含硒,可以增强人体的体力,抗氧化,保护视力,延缓人体的衰老,抗癌。
金银花性寒;味甘;归心、肺、胃经,具有清热解毒,凉散风热的功效。
葛根甘、辛,凉;归脾、胃、肺经,具有解肌退热、生津止渴、透疹、升阳止泻、通经活络、解酒毒等,同时葛根可以解除颈部毛细血管痉挛,用于心脑血管瘀血病证。
番茄浓缩物粉是新疆大田番茄制成原酱,经喷雾干燥后制成天然番茄纯粉,其味酸;甘;性微寒,具有生津止渴;健胃消食的作用。
牛磺酸一种氨基酸,其与甘氨酸和γ氨基丁酸产生化学反应,作为组织和血液的神经抑制剂传递者,可以促进肠道消化,并作为膳食脂肪的乳化剂,具有增强心肌收缩能力并提高运动能力的功效,经常作为高血压和胆固醇高的治疗药物。
在一些实施例中,所述营养组合物由重量份如下的各组分组成:纳豆冻干粉12-18份、红曲10-15份、羊心肽10-13份、金银花6-8份、葛根粉8-10份和牛磺酸1-2份。
在一些实施例中,所述营养组合物由重量份如下的各组分组成:纳豆冻干粉16份、红曲11份、羊心肽12份、金银花8份、葛根粉8份和牛磺酸1份。
在一些实施例中,所述营养组合物还包括D-核糖10-30份和地龙蛋白10-20份。
在一些实施例中,所述营养组合物还包括番茄浓缩物粉8-10份。
在一些实施例中,所述营养组合物为散剂、片剂、颗粒剂、汤剂、口服液、膏剂和饮料中的任意一种。
本发明中纳豆冻干粉配伍地龙蛋白和羊心肽,不仅具有溶化血栓、修复受损的血液细胞、血管细胞的作用,而且可从根本上防止血栓的形成,三者配伍通过及时补充微量元素增强人体的体力,降低血压缓解心血管疾病,不仅可溶解血栓而且防止形成新的血栓;同时葛根的添加可以解除颈部毛细血管痉挛,作为纳豆冻干粉配伍地龙蛋白和羊心肽的佐剂,通经活络疏通血管,防止血栓沾粘血管。红曲不仅具有活血化瘀,其配伍番茄浓缩物粉健脾消食,增强食用者的食欲和体力,配伍牛磺酸促进肠道消化,加快食用者的消化循环速度,改善新陈代谢速度;同时D-核糖可进一步提供热量和能量;而金银花可清除体内的代谢废物,进行清热解毒。本发明通过科学合理的配比在溶解血栓和防止血栓形成的基础上,通经活络疏通血管,防止血栓沾粘血管,且快速清理体内代谢废物,加快新陈代谢速度,全面提高免疫力,从根本上防止血栓再生。本组合物不含有蚓激酶、尿激酶、链激酶等可能引起风险的成分,安全有效。
具体实施方式
为了能够更清楚地理解本发明的上述目的、特征和优点,下面结合具体实施方式对本发明进行进一步的详细描述。需要说明的是,在不冲突的情况下,本发明的实施例及实施例中的特征可以相互组合。
在下面的描述中阐述了很多具体细节以便于充分理解本发明,但是,本发明还可以采用其他不同于在此描述的其他方式来实施,因此,本发明的保护范围并不受下面公开的具体实施例的限制。
实施例1
本实施例提供了一种安全高效溶解血栓和脂质斑块的营养组合物,营养组合物由重量份如下的各组分组成:纳豆冻干粉20份、红曲15份、羊心肽10份、金银花6份、葛根粉6份和牛磺酸1份。
实施例2
本实施例提供了一种安全高效溶解血栓和脂质斑块的营养组合物,营养组合物由重量份如下的各组分组成:D-核糖18份、地龙蛋白15份、纳豆冻干粉14份、红曲8份、羊心肽12份、金银花6份、葛根粉10份和牛磺酸2份。
实施例3
本实施例提供了一种安全高效溶解血栓和脂质斑块的营养组合物,营养组合物由重量份如下的各组分组成:D-核糖30份、地龙蛋白10份、纳豆冻干粉16份、红曲11份、羊心肽12份、金银花8份、葛根粉8份、牛磺酸1份和番茄浓缩物粉10份。
在本实施例中将营养组合物制成片剂,示例性的将D-核糖、地龙蛋白、纳豆冻干粉、红曲、羊心肽、金银花、葛根粉、牛磺酸和番茄浓缩物粉过50-100目筛,过筛后按配比所有原料进行称量;将称量好的原料混合,混合时间为10-20分钟,将混合好的物料进行压片,压片压力为5千牛,填充量为6mm,每片净含量0.6克,每10分钟检查一次净含量,要求净含量达到0.603-0.61克之间;将压片好的营养组合物进行包装,瓶口铝箔封口,装箱;包装后,产品化验室检测合格入库。
实施例4-实施例9中的营养组合物的组分如表1。
纳豆冻干粉 | 红曲 | 羊心肽 | 金银花 | 葛根粉 | 牛磺酸 | D-核糖 | 地龙蛋白 | 番茄浓缩物粉 | |
实施例4 | 10份 | 13份 | 10份 | 8份 | 8份 | 2份 | 25份 | 10份 | 8份 |
实施例5 | 15份 | 6份 | 13份 | 7份 | 10份 | 1份 | 20份 | 15份 | 8份 |
实施例6 | 20份 | 7份 | 15份 | 8份 | 8份 | 2份 | 30份 | 20份 | 9份 |
实施例7 | 12份 | 10份 | 11份 | 10份 | 7份 | 2份 | 30份 | 18份 | 10份 |
实施例8 | 18份 | 15份 | 12份 | 9份 | 9份 | 1份 | 10份 | 18份 | 9份 |
实施例9 | 16份 | 8份 | 13份 | 6份 | 6份 | 1份 | 24份 | 10份 | 10份 |
表1 实施例3-实施例8中中药组合物的组分
对比例1
本对比例中的营养组合物不包括纳豆冻干粉和羊心肽,其他技术特征与实施例3相同。
对比例2
本对比例中的营养组合物不包括金银花和牛磺酸,其他技术特征与实施例3相同。
对比例3
本对比例中的营养组合物不包括地龙蛋白和葛根,其他技术特征与实施例3相同。
实验例10
自由基清除试验
试验原理:DPPH的分光光度法测定原理是依据DHHP在无水乙醇和乙醇-水体系中呈现深紫色,分别在517nm和525nm下有最大吸收。自由基清除剂能够使紫色逐渐退却,根据吸光度的变化测定出DHHP的含量,反应自由基清除剂对DHHP的清除能力。将实施例1-9和对比例1-3中的营养组合物用无水乙醇配置成1mg/mL的溶液。配制浓度为1×10-4mol/L的DPPH·无水乙醇溶液。取2mLDPPH标准溶液,放置在试管中,加入待测样品溶液2mL,放置30min后,在517nm测定吸光度。根据下列公式测定DPPH清除率:
DHHP的清除率=[1-(Ai-Aj)/Ac]×100%;
Ai:2mL待测样品溶液+2mLDPPH溶液的吸光度;
Aj:2mL待测样品溶液+2mL95%乙醇的吸光度;
Ac:2mLDPPH溶液的吸光度+2mL95%乙醇的吸光度。
测定6个月、12个月和18个月的待测样品,保存条件:玻璃瓶密封避光保存,室内阴凉处常规放置。
实验结果见表2。
表2 不同时间段不同样品对DHHP的清除率(%)。
6个月清除率(%) | 12个月清除率(%) | 18个月清除率(%) | |
实施例1 | 90% | 85% | 80% |
实施例2 | 93% | 90% | 86% |
实施例3 | 98% | 94% | 90% |
实施例4 | 96% | 92% | 88% |
实施例5 | 97% | 92% | 87% |
实施例6 | 96% | 93% | 88% |
实施例7 | 95% | 93% | 90% |
实施例8 | 94% | 92% | 87% |
实施例9 | 95% | 90% | 80% |
对比例1 | 50% | 40% | 20% |
对比例2 | 55% | 44% | 32% |
对比例3 | 60% | 50% | 43% |
实施例11
选择500名志愿者,男女各250名,年龄范围为30~79岁,平均年龄42.8岁,均符合诊断标准、排除肝肾内分泌疾患及药物所致的高血脂患者。将志愿者随机平均分为10组,每组50人。
观察方法
试验组1-5每天服用本发明实施例3的样品,每人每天2次,一次1片(每片净含量0.6克);对照组1-5每天分别服用对比例1-3的样品,每人每天2次,一次1片(每片净含量0.6克)。
服用6-8小时医院检测D-2聚体,检测结果试验组1-5每天服用本发明实施例3的样品相较于对比例1-3可有效降低D-2聚体指标,证明溶栓作用。志愿者服用3-7天后,医院检测血流,服用本发明实施例3的样品相较于对比例1-3可有效降改善血液循环。
服用本发明实施例3的样品90天后进行医院检测颈动脉彩超,其中总有效率不低于95%,减小班块面积10-30%。
示例性的,黄某,48岁,男性,于2021年1月27日在河南中医药大学第一附属医院初次进行彩超检测,其中超声所见,双侧锁骨下动脉、颈总动脉、颈内动脉和颈外动脉内径正常,双侧颈动脉局部内膜增厚,厚处约1.2mm,黏膜面光滑,右侧锁骨下动脉起始后壁见一12.2×3.4mm回声斑块,左侧颈总动脉后壁见一12×2.7mm低回声斑块,余管腔内未见明显斑块;其中斑块处血流充盈缺损,余管腔内血流充盈好,血流速度正常。
黄某服用于本发明实施例3的样品每天2次,一次1片(每片净含量0.6克),2021年5月27日再次进行彩超检测,其中超声所见,右侧锁骨下动脉起始后壁见一9.9×2.5mm回声斑块,左侧颈总动脉后壁见一9.9×2.1mm低回声斑块。黄某继续服用本发明实施例3的样品,2021年7月31日再次进行彩超检测,其中超声所见,右侧锁骨下动脉起始后壁见一8.1×2.7mm回声斑块,左侧颈总动脉后壁见一7.1×1.9mm低回声斑块。
再例如,姚某52岁,男性,双侧颈动脉内-中膜局部略增厚,双侧颈总动脉窦部斑块形成,服用于本发明实施例3的样品每天2次,一次1片(每片净含量0.6克),于7日后再次检测发现可有效降改善血液循环。
此外,应当理解,虽然本说明书按照实施方式加以描述,但并非每个实施方式仅包含一个独立的技术方案,说明书的这种叙述方式仅仅是为清楚起见,本领域技术人员应当将说明书作为一个整体,各实施例中的技术方案也可以经适当组合,形成本领域技术人员可以理解的其他实施方式。
以上仅为本发明的优选实施例而已,并不用于限制本发明,对于本领域的技术人员来说,本发明可以有各种更改和变化。凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (6)
1.一种安全高效溶解血栓和脂质斑块的营养组合物,其特征在于,所述营养组合物由重量份如下的各组分组成:纳豆冻干粉10-20份、红曲6-15份、羊心肽10-15份、金银花6-10份、葛根粉6-10份和牛磺酸1-2份。
2.根据权利要求1所述的营养组合物,其特征在于,所述营养组合物由重量份如下的各组分组成:纳豆冻干粉12-18份、红曲10-15份、羊心肽10-13份、金银花6-8份、葛根粉8-10份和牛磺酸1-2份。
3.根据权利要求1所述的营养组合物,其特征在于,所述营养组合物由重量份如下的各组分组成:纳豆冻干粉16份、红曲11份、羊心肽12份、金银花8份、葛根粉8份和牛磺酸1份。
4.根据权利要求1-3任一所述的营养组合物,其特征在于,还包括D-核糖10-30份和地龙蛋白10-20份。
5.根据权利要求4所述的营养组合物,其特征在于,还包括番茄浓缩物粉8-10份。
6.根据权利要求5所述的营养组合物,其特征在于:所述营养组合物为散剂、片剂、颗粒剂、汤剂、口服液、膏剂和饮料中的任意一种。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111620451.1A CN114431412A (zh) | 2021-12-28 | 2021-12-28 | 一种安全高效溶解血栓和脂质斑块的营养组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111620451.1A CN114431412A (zh) | 2021-12-28 | 2021-12-28 | 一种安全高效溶解血栓和脂质斑块的营养组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114431412A true CN114431412A (zh) | 2022-05-06 |
Family
ID=81365189
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111620451.1A Pending CN114431412A (zh) | 2021-12-28 | 2021-12-28 | 一种安全高效溶解血栓和脂质斑块的营养组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114431412A (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106262803A (zh) * | 2016-07-14 | 2017-01-04 | 新乡医学院 | 一种强抗氧化预防动脉粥样硬化的组合物及其应用 |
CN109430664A (zh) * | 2018-08-28 | 2019-03-08 | 威海养经堂医药科技有限公司 | 一种强芯肽固体饮料 |
CN110051826A (zh) * | 2019-05-17 | 2019-07-26 | 广东双骏生物科技有限公司 | 一种具有改善心血管功能的组合物及其制备方法 |
CN110859869A (zh) * | 2019-12-20 | 2020-03-06 | 中国中医科学院中医药科技合作中心 | 一种预防和治疗心脑血管疾病的组合物及其制备方法 |
CN111406950A (zh) * | 2020-04-29 | 2020-07-14 | 北京大元藏宝堂健康管理有限公司 | 一种复合多肽粉 |
-
2021
- 2021-12-28 CN CN202111620451.1A patent/CN114431412A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106262803A (zh) * | 2016-07-14 | 2017-01-04 | 新乡医学院 | 一种强抗氧化预防动脉粥样硬化的组合物及其应用 |
CN109430664A (zh) * | 2018-08-28 | 2019-03-08 | 威海养经堂医药科技有限公司 | 一种强芯肽固体饮料 |
CN110051826A (zh) * | 2019-05-17 | 2019-07-26 | 广东双骏生物科技有限公司 | 一种具有改善心血管功能的组合物及其制备方法 |
CN110859869A (zh) * | 2019-12-20 | 2020-03-06 | 中国中医科学院中医药科技合作中心 | 一种预防和治疗心脑血管疾病的组合物及其制备方法 |
CN111406950A (zh) * | 2020-04-29 | 2020-07-14 | 北京大元藏宝堂健康管理有限公司 | 一种复合多肽粉 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2010106022A (ja) | セルライト及びセルライトに付随する非審美的な外観の低減用の薬剤を含む組成物、及び当該組成物を含む製剤 | |
CN103800661A (zh) | 一种增强免疫力、缓解体力疲劳的组合物及含其制剂 | |
CN109090597A (zh) | 一种辅助降三高组合物及其制备方法和应用 | |
CN105232907A (zh) | 一种补肾壮阳饮料及其制备方法 | |
AU2005258551A1 (en) | Fat combustion accelerator | |
JP2006193502A (ja) | アディポネクチン調節剤、それを含有する飲食品、食品添加物及び医薬 | |
CN108813610A (zh) | 一种用于提高免疫力的雪莲组合物及其应用 | |
CN108813465A (zh) | 一种无花果功能咀嚼片及其制备方法 | |
CN102688471A (zh) | 一种具有抗疲劳作用的复方制剂 | |
CN107648512A (zh) | 一种改善人体微循环的中药组合物及制备方法 | |
KR100518179B1 (ko) | 성기능 개선 조성물 | |
CN114431412A (zh) | 一种安全高效溶解血栓和脂质斑块的营养组合物 | |
JP2001163795A (ja) | α−グルコシダーゼ阻害剤 | |
JPWO2005082390A1 (ja) | 脂肪蓄積抑制剤 | |
KR101058422B1 (ko) | 한방 건강 보조 식품 및 그의 제조방법 | |
KR101093006B1 (ko) | 미생물을 이용한 우황 청심원 원료 함유 건강식품의 제조방법 및 그 제조방법에 의해 제조된 건강식품 | |
CN107080240A (zh) | 一种缓解气滞血瘀的保健食品调理剂及其制备方法 | |
CN113117054A (zh) | 治疗和预防心脑血管疾病的中药组合物及其制备方法 | |
CN110420320A (zh) | 一种清除痛风发病基础的中药组合物 | |
CN114712424B (zh) | 一种具有解酒保肝作用的中药制剂及其制备方法和应用 | |
CN106728631A (zh) | 一种治疗高血压患者伴有动脉粥样硬化症的中药制剂 | |
AU5778801A (en) | Improvements in effervescent tablet manufacture | |
KR20180078781A (ko) | 절식 보조용 조성물 | |
CN117357635A (zh) | 一种治疗高尿酸和痛风性关节炎的中药组合物及其制备方法 | |
CN105770474A (zh) | 一种抗红斑狼疮联合免疫用药物及其制备方法、用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |